These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32902324)

  • 1. Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.
    Scheers E; Borgmans C; Keung C; Bohets H; Wynant I; Poggesi I; Cuyckens F; Leclercq L; Mamidi RNVS
    Xenobiotica; 2021 Feb; 51(2):177-193. PubMed ID: 32902324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
    Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
    Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism and disposition of a potent and selective JNK inhibitor [14C]tanzisertib following oral administration to rats, dogs and humans.
    Atsriku C; Hoffmann M; Ye Y; Kumar G; Surapaneni S
    Xenobiotica; 2015 May; 45(5):428-41. PubMed ID: 25482583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.
    Hong H; Su H; Sun H; Allentoff A; Ekhato IV; Chando T; Caceres-Cortes J; Roongta V; Iyer RA; Humphreys WG; Christopher LJ
    Drug Metab Dispos; 2010 Jul; 38(7):1189-201. PubMed ID: 20363952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
    Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.
    Mamidi RN; Cuyckens F; Chen J; Scheers E; Kalamaridis D; Lin R; Silva J; Sha S; Evans DC; Kelley MF; Devineni D; Johnson MD; Lim HK
    Drug Metab Dispos; 2014 May; 42(5):903-16. PubMed ID: 24568888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.
    Nishina T; Takahashi S; Iwasawa R; Noguchi H; Aoki M; Doi T
    Invest New Drugs; 2018 Jun; 36(3):424-434. PubMed ID: 28965185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Species differences in the biotransformation of an alpha 4 beta 2 nicotinic acetylcholine receptor partial agonist: the effects of distinct glucuronide metabolites on overall compound disposition.
    Shaffer CL; Gunduz M; Ryder TF; O'Connell TN
    Drug Metab Dispos; 2010 Feb; 38(2):292-301. PubMed ID: 19910512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans.
    Balani SK; Woolf EJ; Hoagland VL; Sturgill MG; Deutsch PJ; Yeh KC; Lin JH
    Drug Metab Dispos; 1996 Dec; 24(12):1389-94. PubMed ID: 8971147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.
    Weinz C; Schwarz T; Kubitza D; Mueck W; Lang D
    Drug Metab Dispos; 2009 May; 37(5):1056-64. PubMed ID: 19196845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.
    Gong J; Gan J; Caceres-Cortes J; Christopher LJ; Arora V; Masson E; Williams D; Pursley J; Allentoff A; Lago M; Tran SB; Iyer RA
    Drug Metab Dispos; 2011 May; 39(5):891-903. PubMed ID: 21289073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biotransformation of an alpha4beta2 nicotinic acetylcholine receptor partial agonist in sprague-dawley rats and the dispositional characterization of its N-carbamoyl glucuronide metabolite.
    Shaffer CL; Ryder TF; Venkatakrishnan K; Henne IK; O'Connell TN
    Drug Metab Dispos; 2009 Jul; 37(7):1480-9. PubMed ID: 19339375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Plasma Protein Binding on the Pharmacokinetics of Erdafitinib: Results of an Integrated Cross-Study Analysis.
    Li LY; Guo Y; Gonzalez M; Ouellet D
    J Clin Pharmacol; 2020 Mar; 60(3):391-399. PubMed ID: 31602692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
    Beconi MG; Reed JR; Teffera Y; Xia YQ; Kochansky CJ; Liu DQ; Xu S; Elmore CS; Ciccotto S; Hora DF; Stearns RA; Vincent SH
    Drug Metab Dispos; 2007 Apr; 35(4):525-32. PubMed ID: 17220241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPLC-NMR with severe column overloading: fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126.
    Lenz EM; D'Souza RA; Jordan AC; King CD; Smith SM; Phillips PJ; McCormick AD; Roberts DW
    J Pharm Biomed Anal; 2007 Feb; 43(3):1065-77. PubMed ID: 17030109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
    Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
    Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biotransformation Pathways and Metabolite Profiles of Oral [
    Pusalkar S; Zhou X; Li Y; Cohen L; Yang JJ; Balani SK; Xia C; Shyu WC; Lu C; Venkatakrishnan K; Chowdhury SK
    Drug Metab Dispos; 2020 Mar; 48(3):217-229. PubMed ID: 31911485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
    Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
    Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs.
    Huskey SE; Dean BJ; Doss GA; Wang Z; Hop CE; Anari R; Finke PE; Robichaud AJ; Zhang M; Wang B; Strauss JR; Cunningham PK; Feeney WP; Franklin RB; Baillie TA; Chiu SH
    Drug Metab Dispos; 2004 Feb; 32(2):246-58. PubMed ID: 14744948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reductive isoxazole ring opening of the anticoagulant razaxaban is the major metabolic clearance pathway in rats and dogs.
    Zhang D; Raghavan N; Chen SY; Zhang H; Quan M; Lecureux L; Patrone LM; Lam PY; Bonacorsi SJ; Knabb RM; Skiles GL; He K
    Drug Metab Dispos; 2008 Feb; 36(2):303-15. PubMed ID: 17984286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.